This Morning's Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen Therapeutics

NEW YORK, Feb. 1, 2018 /PRNewswire/ strives to bring the best free research to the investment community.  Today we are offering reports on APTO, ATHX, AVEO, and AVIR which can be accessed for free by signing up to On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.12%; the Dow Jones Industrial Average edged 0.28% higher; and the S&P 500 was up 0.05%. US markets made broad based gains with six out of nine sectors finishing the day in green. Pre-market today, reviews these four Biotechnology stocks: Aptose Biosciences Inc. (NASDAQ: APTO), Athersys Inc. (NASDAQ: ATHX), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), and Aviragen Therapeutics Inc. (NASDAQ: AVIR). All you have to do is sign up today for this free limited time offer by clicking the link below.

Aptose Biosciences

Mississauga, Canada headquartered Aptose Biosciences Inc.'s stock finished Wednesday's session 0.33% lower at $3.02. A total volume of 123,397 shares was traded. The Company's shares have advanced 34.82% in the past month, 100.00% over the previous three months, and 202.00% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 33.32% and 91.24%, respectively. Furthermore, shares of Aptose Biosciences, which discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada, have a Relative Strength Index (RSI) of 58.76. Get the full research report on APTO for free by clicking below at:


Shares in Cleveland, Ohio headquartered Athersys Inc. ended at $1.75, down 2.23% from the last trading session. The stock recorded a trading volume of 730,402 shares, which was above its three months average volume of 623.72 thousand shares. The Company's shares have gained 60.55% in the last twelve months. The stock is trading below its 50-day moving average by 6.48%. Moreover, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have an RSI of 36.70. ATHX's complimentary research coverage is a few simple steps away at:

AVEO Pharmaceuticals

Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc.'s stock ended yesterday's session 6.95% higher at $3.23 with a total trading volume of 3.93 million shares, which was above its three months average volume of 1.59 million shares. The Company's shares have advanced 15.77% in the past month and 420.97% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 10.40% and 31.14%, respectively. Additionally, shares of AVEO Pharma, which develops targeted therapies for cancer and related diseases, have an RSI of 63.73. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AVEO at:

Aviragen Therapeutics

On Wednesday, shares in Alpharetta, Georgia headquartered Aviragen Therapeutics Inc. recorded a trading volume of 180,984 shares. The stock finished the day 0.46% higher at $0.58. The Company's shares have advanced 3.25% in the last month. The stock is trading below its 50-day moving average by 1.66%. Furthermore, shares of Aviragen Therapeutics, which focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide, have an RSI of 43.91. Aspiring Member, please take a moment to register below for your free research report on AVIR at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.